Literature DB >> 8103352

Coping with toxicities of docetaxel (Taxotere).

D Schrijvers1, J Wanders, L Dirix, A Prove, I Vonck, A van Oosterom, S Kaye.   

Abstract

BACKGROUND: In phase II studies of the EORTC-ECTG, acute hypersensitivity reaction, edema and skin toxicity were important side effects of docetaxel (TaxotereTM). PATIENTS AND METHODS: Fifty patients with solid tumors were treated with docetaxel at the University Hospital of Antwerp. Of these, 28% developed an acute hypersensitivity reaction and 20% edema. Twelve and three hours before the next docetaxel administrations those with the acute hypersensitivity reaction were subsequently pretreated orally with 32 mg of methylprednisolone, 10 mg of cetirizine and 1 mg of ketotifen.
CONCLUSIONS: The acute hypersensitivity reaction could be completely blocked in all but in 1 of 14 patients, and this pretreatment schedule had an important prophylactic effect on edema formation. Skin toxicity was successfully treated with an ointment of glycerin and chlorhexidine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103352     DOI: 10.1093/oxfordjournals.annonc.a058599

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  24 in total

Review 1.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.

Authors:  Carmel Jacobs; Brian Hutton; Sasha Mazzarello; Stephanie Smith; Anil Joy; Eitan Amir; Mohammed F K Ibrahim; Nancy Gregario; Kelly Daigle; Lori Eggert; Mark Clemons
Journal:  Support Care Cancer       Date:  2015-05-03       Impact factor: 3.603

Review 3.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 4.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

Review 5.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  An exploratory study of frequent pain measurement in a cancer clinical trial.

Authors:  J Ingham; A Seidman; T J Yao; J Lepore; R Portenoy
Journal:  Qual Life Res       Date:  1996-10       Impact factor: 4.147

7.  Docetaxel-induced nail changes--a neurogenic mechanism: a case report.

Authors:  Gunnar Wasner; Felix Hilpert; Jörn Schattschneider; Andreas Binder; Jacobus Pfisterer; Ralf Baron
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

8.  New cutaneous toxicities with generic docetaxel: are the excipients guilty?

Authors:  Margarita Garrido-Siles; Jose Javier Arenas-Villafranca; Elísabeth Pérez-Ruiz; M Francisca de Linares Fernández; Begoña Tortajada; Francisco Rivas-Ruiz; Vicente Faus; Antonio Rueda
Journal:  Support Care Cancer       Date:  2014-12-10       Impact factor: 3.603

Review 9.  Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.

Authors:  Matthieu Picard; Mariana C Castells
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

10.  Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.

Authors:  Rae Young Kang; Kyung Sook Yoo; Hyeon Ju Han; Ju-Yeun Lee; Se-Hoon Lee; Dong-Wan Kim; Yu Jeung Lee
Journal:  Support Care Cancer       Date:  2016-09-30       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.